Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer.

The choice of adjuvant systemic therapy is based on targeted therapy in line with the St. Gallen Consensus meeting. In addition to the traditional parameters, the panel recommended the use of proliferation markers and multigene assays. The purpose of the present study was to evaluate the clinical si... View More